NCT07218952Enrolling by invitation
Radiation Therapy (RT) for Parkinson's Disease (PD)
Ultra-low Dose, DaT-SPECT-guided Radiation Therapy for the Treatment of Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the use of ultra-low, anti-inflammatory doses of radiation therapy (RT) for the treatment of Parkinson's Disease (PD). In this study, the TrueBeam LINAC utilizes a linear accelerator (LINAC) for the delivery of radiation therapy. Dynamic conformal arc (DCA) therapy will be used to deliver a total of five (5) once-a-day radiation treatments (RT) using DaT-SPECT (Dopamine Transporter-Single-Photon Emission Computed Tomography) and MRI imaging to guide radiation treatment planning.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 17 Oct 2025
- Start date
- 20 Jan 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Parkinson disease
- NCT number
- NCT07218952
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 20 Jan 2026 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant dementia diagnosis or concerns of other memory disorder
Other illness
- Parkinson's Disease medication changes within the last 3 months
- Receipt of radiation therapy for Parkinson's Disease outside Mayo Clinic, Rochester
Who the study is looking for
- Age ≥ 45 and ≤ 70 years
- Diagnosis of Parkinson's disease by a Movement Disorder Neurologist
- Confirmation of unilateral Parkinson's disease by Dopamine Transporter (DaT) scan
- A score of 2 or less on the modified Hoehn and Yahr scale
- ECOG Performance Status (PS) ≤ 2 (Appendix I).
- No known genetic causes or predisposition to Parkinson's disease or related diseases.
- Ability to complete questionnaires, neurological exam, and follow-up imaging independently or with assistance
- Ability to provide written informed consent
- Willing to provide mandatory blood samples for correlative research purposes
- Willing to return to enrolling institution for follow-up
Age in the registry: 45 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.